Research programme: DNA vaccines - Greffex
Alternative Names: Avian influenza vaccine - Greffex; Aznthrax vaccine - Greffex; Dengue vaccine - Greffex; Ebola virus vaccine - Greffex; GREANX; GREDEN/V1-4; GREFLU/CAL; GREFLU/VIE; GreVac™ vaccines; GREVAX; H1N1 vaccine - Greffex; H7N9 vaccine - Greffex; HIV vaccine - Greffex; MERS-CoV vaccine - Greffex; Middle east respiratory syndrom coronavirus vaccine - Greffex; Plague vaccine - Greffex; Tuberculosis vaccine - Greffex; Universal influenza vaccine - GreffexLatest Information Update: 28 Sep 2023
At a glance
- Originator Greffex Inc
- Class Anthrax vaccines; Bacterial vaccines; Dengue vaccines; DNA vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza virus vaccines; Lyme disease vaccines; Plague vaccines; Tuberculosis vaccines; Viral vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Lyme disease; Middle East respiratory syndrome coronavirus; Zika virus infection
- No development reported Anthrax; Coronavirus infections; Dengue; Ebola virus infections; HIV infections; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza virus infections; Plague; Tuberculosis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Coronavirus-infections in USA (Parenteral)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)